How to Buy Crispr Therapeutics Ag Stock
Crispr Therapeutics Ag
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases.
Crispr Therapeutics Ag stock last closed at $47.99, down 0.93% from the previous day, and has decreased 14.7% in one year. It has underperformed other stocks in the Biotechnology industry by 0.01 percentage points. Crispr Therapeutics Ag stock is currently +8.77% from its 52-week low of $44.12, and -38.85% from its 52-week high of $78.48.
There are currently 96.45M CRSP shares outstanding. The market value of CRSP is $4.63B. In the last 24 hours, 1.02M CRSP shares were traded.
How to Buy Crispr Therapeutics Ag Stock
Wondering how to invest in Crispr Therapeutics Ag stock? Here's how.
- Choose where to buy Crispr Therapeutics Ag stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Crispr Therapeutics Ag stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Pick your payment method and add your details.
- Analyze Crispr Therapeutics Ag stock: The Crispr Therapeutics Ag ticker symbol is CRSP. Is Crispr Therapeutics Ag stock a good investment? Should you buy shares of CRSP? How do CRSP's underlying business fundamentals look? Do top analysts think Crispr Therapeutics Ag is a good buy? Why has CRSP's stock price moved recently? (Hint: Our stock market analysis website can help you understand if CRSP is a good stock to buy).
- Make your CRSP purchase: Decide if you will purchase CRSP shares at the current market price or use a limit order to buy CRSP stock at a specific price.
- Monitor your CRSP investment: Create a watchlist to track your new investment in Crispr Therapeutics Ag stock.
Step 1: Choose where to buy Crispr Therapeutics Ag stock
You need a brokerage account in order to access the NASDAQ market and buy CRSP stock.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, you need to fill out some personal information so you can invest in CRSP today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new brokerage account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've filled out your info on one of the best stock apps, you need to deposit funds:
Watch the walkthrough below for more details transferring funds into your investment account.
Step 4: Analyze Crispr Therapeutics Ag stock
After you have figured out the best place to buy Crispr Therapeutics Ag stock, it's important to research their stock before you buy, so you actually comprehend the risk as well as the opportunity.
Crispr Therapeutics Ag shares quick numbers
Crispr Therapeutics Ag Due Diligence Checks
WallStreetZen was built to help part-time investors do more accurate fundamental analysis quickly.
You can see all of the due diligence checks on CRSP's stock page.
Is CRSP stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge CRSP's fair value.
Using relative valuations metrics:
- CRSP may be undervalued based on its P/B ratio of 2.55x, relative to Biotechnology industry P/B ratio of 5.24x
You can access additional valuation research on CRSP's stock here.
CRSP Financials at a glance
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the CRSP balance sheet.
- CRSP has cash burn of 401176000. It has enough cash and short-term investments to cover this for at least one year.
- CRSP has $2.45B in cash and short term investments. This is enough to cover its annual cash burn of $401.18M.
- There are more short-term assets than long-term liabilities on the CRSP balance sheet.
Negative Health Checks:
- CRSP has a relatively high debt to equity ratio of 0.5.
- CRSP profit margin has gone down from -1,023.6% to -13,856.5% in the past year.
- Total CRSP debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Crispr Therapeutics Ag stock, according to Wall Street analysts?
Out of 9 Equities analysts who research CRSP, the consensus analyst rating on CRSP is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent CRSP Analyst Ratings
Geulah Livshits, a top 3% analyst from Chardan Capital maintains CRSP with a strong buy rating and raises their CRSP price target from $74.00 to $76.00, on Feb 17, 2026.
Chardan Capital's Geulah Livshits raised their price target on Crispr Therapeutics Ag (NASDAQ: CRSP) by 2.7% from $74 to $76 on 2026/02/17. The analyst maintained their Strong Buy rating on the stock.
CRISPR Therapeutics AG reported its Q4 and FY 2025 earnings.
Revising their model and raising their price target, Livshits headlined from the print/earnings call:
- The company is actively expanding its in vivo cardiovascular editing and siRNA trademarks.
- It has recently made preclinical progress toward in vivo CAR-T capabilities.
Earnings Report
CRISPR Therapeutics Ag reported:
For Q4 2025:
- Loss per share of $1.37, which missed the Zacks Consensus Estimate of $(1.15) and Q4 2024’s $(0.44).
- Revenue of $0.86M, which missed the Zacks Consensus Estimate by 78.42% and Q4 2024’s $35.69M.
For FY 2025:
- Loss per share of $6.47, compared to FY 2024’s loss of $4.34.
- Revenue of $3.51M, compared to FY 2025’s $37.31M.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO Samarth Kulkarni, Ph.D. commented: “As we close out Q4, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline.
“We made meaningful advances across multiple clinical and preclinical programs, including encouraging data from zugo-cel in autoimmune disease and oncology, continued global uptake of CASGEVY, and important developments across our in vivo liver editing portfolio, and momentum in our siRNA collaboration with Sirius Therapeutics.
“At the same time, we continue to strengthen our platform capabilities to support long-term value creation.
“Together, these developments reflect continued execution across the portfolio.”
Tyler Van Buren, a bottom 5% analyst from TD Cowen maintains CRSP with a hold rating and raises their CRSP price target from $40.00 to $45.00, on Feb 13, 2026.
Liisa Bayko, a top 12% analyst from Evercore ISI Group maintains CRSP with a buy rating and raises their CRSP price target from $62.00 to $74.00, on Feb 13, 2026.
Gil Blum, a top 3% analyst from Needham maintains CRSP with a buy rating and raises their CRSP price target from $80.00 to $82.00, on Feb 13, 2026.
You can dive deeper into what analysts are saying on the Crispr Therapeutics Ag stock forecast page.
CRSP Trading Indicators
Is CRSP Making Money?
Last year, CRSP revenue was $4.10M. Over the past 5 year, CRSP's revenue has increased by 30.1% per year. This was slower than the Biotechnology industry average of 33.95%.
Dive into CRSP's earnings and revenue performance here.
Are CRSP insiders buying or selling the stock?
Over the past year, insiders at CRSP have sold more shares than they have bought.
Naimish Patel, Chief Medical Officer of CRSP, was the latest CRSP insider to sell. They sold $210,577.32 worth of CRSP stock on May 29, 2026.
Get more info about who owns CRSP stock here.
Can I rely on CRSP as an income stream?
No, Crispr Therapeutics Ag doesn't provide an income stream by paying out dividends.
CRSP Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your CRSP purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price limit, place a limit order.
Press the Open button and your broker will place your order.
If you require more help with buying stocks on eToro, click the how to video below:
Step 6: Monitor your CRSP investment
Now that you own some CRSP shares, you'll want to stay up-to-date on your shares.
Start a watchlist to see the latest developments about your CRSP stock.
CRSP Feed
How to Buy Stock in Crispr Therapeutics Ag
To summarize, here are the 6 steps to buy Crispr Therapeutics Ag stock:
- Choose where to buy Crispr Therapeutics Ag stock
- Sign up for your brokerage account
- Deposit money your investment account
- Analyze Crispr Therapeutics Ag stock
- Make your CRSP purchase
- Monitor your CRSP investment
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep tabs on your new investment in Crispr Therapeutics Ag, add CRSP to your watchlist by clicking the button below.
Other Articles You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.